Earnings summaries and quarterly performance for MIMEDX GROUP.
Executive leadership at MIMEDX GROUP.
Joseph H. Capper
Detailed
Chief Executive Officer
CEO
DR
Doug Rice
Detailed
Chief Financial Officer
KM
Kimberly Maersk-Moller
Detailed
Chief Commercial Officer
RS
Ricci S. Whitlow
Detailed
Executive Vice President and Chief Operating Officer
WF
William F. Hulse IV
Detailed
General Counsel and Chief Administrative Officer
Board of directors at MIMEDX GROUP.
Research analysts who have asked questions during MIMEDX GROUP earnings calls.
CB
Carl Byrnes
Northland Capital Markets
4 questions for MDXG
Also covers: ALVO, BLFS, BWAY +6 more
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for MDXG
Also covers: AVDL, BFLY, BVS +17 more
RO
Ross Osborn
Cantor Fitzgerald
4 questions for MDXG
Also covers: AXGN, CERS, CVRX +12 more
AP
Anthony Petrone
Mizuho Group
2 questions for MDXG
Also covers: ADMA, ALC, BSX +22 more
Bradley Bowers
Mizuho Securities USA LLC
2 questions for MDXG
Also covers: COO
BO
Brooks O'Neil
Lake Street Capital Markets
2 questions for MDXG
Also covers: ARAY, ATEC, BBNX +11 more
Recent press releases and 8-K filings for MDXG.
MIMEDX Secures Exclusive U.S. Distribution for RegenKit®-Wound Gel
MDXG
Product Launch
New Projects/Investments
- MiMedx Group, Inc. has secured an exclusive agreement with Regen Lab USA LLC for the U.S. distribution of RegenKit®-Wound Gel.
- RegenKit®-Wound Gel is an FDA-approved (2022) autologous platelet-rich plasma and thrombin serum wound gel, nationally covered by CMS and LCD for chronic wounds under HCPCS code G0465.
- This addition expands MIMEDX's Advanced Wound Care portfolio with a differentiated autologous solution, strengthening its competitive position ahead of January 1, 2026, LCD implementation.
2 days ago
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
MDXG
New Projects/Investments
- MiMedx Group, Inc. (MIMEDX) commented on the Centers for Medicare and Medicaid Services (CMS) CY 2026 Physician Fee Schedule (PFS) final rule, which was published on Friday.
- MIMEDX believes the new PFS will help reduce fraud, waste, and abuse in the skin substitute industry, leading to increased market stability and predictability.
- CEO Joseph H. Capper stated that the final rule, which aligns with the July proposal, presents a significant opportunity for MIMEDX due to its competitive advantages, including efficient operations, a strong commercial organization, best-in-class technology, a robust IP portfolio, and an excellent balance sheet.
- The company plans to leverage its strengths to gain market share as the market adapts to the new reimbursement environment and will continue to advocate for further improvements.
Nov 3, 2025, 2:15 PM
MiMedx Reports Record Q3 2025 Results and Raises Full-Year Guidance
MDXG
Earnings
Guidance Update
Product Launch
- MiMedx achieved record Q3 2025 revenue of $114 million, marking 35% year-over-year net sales growth, and reported adjusted EBITDA of $35 million, or 31% of net sales.
- The company has raised its full-year 2025 revenue growth guidance to mid to high teens and expects adjusted EBITDA margin to be at least in the mid-20% range.
- Net cash increased by $23 million in Q3 to $124 million, with projections to end 2025 with a net cash balance exceeding $150 million.
- The surgical business demonstrated 26% growth in Q3 2025, while the wound franchise grew 40%.
- MiMedx is preparing for Medicare reimbursement reforms, anticipated to be implemented in early 2026, which include a proposed fixed payment of $125.38 per square centimeter for skin substitutes, and expects to outperform the market following these changes.
Oct 29, 2025, 8:30 PM
MiMedx Group, Inc. Reports Record Q3 2025 Financial Results and Raises Full-Year Outlook
MDXG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- MiMedx Group, Inc. reported record net sales of $114 million for the third quarter of 2025, representing a 35% increase year-over-year. This growth was primarily driven by a 40% increase in Wound product sales and a 26% increase in Surgical product sales.
- For the third quarter of 2025, the company achieved GAAP net income of $17 million and diluted earnings per share of $0.11.
- Adjusted EBITDA for Q3 2025 was $35 million, or 31% of net sales.
- As of September 30, 2025, MiMedx Group, Inc. had $142 million in cash and cash equivalents, with a net cash position of $124 million after debt.
- The company raised its 2025 financial outlook, now expecting net sales growth in the mid-to-high teens and an Adjusted EBITDA margin of at least mid-20% for the full year.
Oct 29, 2025, 8:07 PM
Quarterly earnings call transcripts for MIMEDX GROUP.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more